Altos Labs

Mgoes (bio/acc 🤖💉)

@m_goes_distance

ladies and gentlemen i present to you Q2 2026 here's what's coming in biotech and human enhancement: > Life Biosciences enrolls first patients in the FDA-approved age reversal trial. epigenetic reprogramming in humans, results expected by year end > FDA rules on Lilly's oral GLP-1 orforglipron by April 10. if approved, the first pill that does what Ozempic does > Kyverna files for first ever CAR-T approval for autoimmune disease. one injection, drug-free remission for lupus > Neuralink moves to high-volume BCI production and automated surgical implantation. the brain-computer interface goes from experiment to infrastructure > XPRIZE Healthspan awards $10M each to top 10 finalists to run one-year human trials restoring physical and cognitive function > Retro Biosciences and Altos Labs both expected to advance toward human study- the $3B+ epigenetic reprogramming bets finally hit the clinic > personal health data goes institutional- WHOOP at $10B, Abbott and Mayo Clinic in the cap table, sovereign wealth backing biometric infrastructure > Enhanced Games, May 21-24, Las Vegas, Resorts World- the first sports competition where PEDs are not just allowed but the point. $1M prize for breaking the 100m sprint or 50m freestyle world record. the steroid Olympics is real. are you paying attention? bio/acc

Eric Topol

@EricTopol

Will cell reprogramming with stem cell factors reverse aging? A pilot trial in eye disease will soon be the first test at the tissue level. https://t.co/PnRf1gZNY3 Feature @Nature by @heidiledford @altos_labs @lifebiosciences https://t.co/JMMdgglPrg

David Sinclair

@davidasinclair

NEW STUDY: Epigenetic drift is redefined as “mesenchymal drift”, with aged cells undergoing EMT, typically a cell ID alteration in development & wound healing, not diseases. Drift is reversed by OSK(M) reprogramming! Another step forward 👏 @altos_labs https://t.co/G04FkMk9uS https://t.co/AZ8cMWieVI

Ashlee Vance

@ashleevance

Not sure how I missed this, but it's freaking nuts. Altos Labs is hitting organs with Yamanaka factors ahead of transplants and basically making the organs younger, which in turn makes the transplant work better https://t.co/XVfGHFVbd7 https://t.co/b8Bb26JCwo

Shanaka Anslem Perera ⚡

@shanaka86

GSK paid $720 million at an 84% premium for David Sinclair’s last big idea. It was built on a red wine molecule called resveratrol. Pfizer and Amgen independently proved the core assay was an artifact of a fluorescent dye. GSK shut Sirtris down by 2013. Every dollar evaporated. In March 2024, fellow longevity scientists forced Sinclair to resign as president of the Academy for Health and Lifespan Research after a company he co-founded claimed a dog supplement had reversed aging. Matt Kaeberlein, co-founder of the Dog Aging Project and one of the foremost experts in canine aging science, called the claim dishonest and publicly renounced his membership. That same scientist just received FDA clearance for the first human trial of cellular age reversal in history. Trial ID: NCT07290244. The thesis is simple enough to be either profound or wrong. Aging is not hardware failure. Your DNA sequence remains intact. What degrades is the epigenome, the chemical tagging system that tells each cell which genes to read. Decades of damage and repair introduce noise into those tags until cells forget what they are supposed to do. Sinclair’s lab took three of four Yamanaka factors, excluded c-Myc, the one linked to tumor formation, and delivered them to the retinal cells of blind mice. Vision returned. The study made the cover of Nature in December 2020. They then induced optic nerve stroke injuries in nonhuman primates and reported restored function. No independent lab has replicated either result. ER-100 is the drug. Phase 1, safety-focused, not efficacy. Injected directly into the eye. Up to 12 patients, six with open-angle glaucoma and six with NAION. One patient enrolled first, then a 28-day observation window, then two more, then another 28-day wait before any dose adjustment. Results potentially by end of 2026. The money tells you the mechanism is being taken seriously independent of the man. Altos Labs launched with $3 billion. Sam Altman backed Retro Biosciences with $180 million. New Limit closed a $130 million Series B in May 2025. Hundreds of millions more across smaller players. Life Biosciences is simply first to reach the clinic. Here is the falsification event. If damaged optic nerves regenerate in human patients under controlled conditions, the Information Theory of Aging graduates from controversial hypothesis to therapeutic paradigm and medicine reorganizes around a single targetable root cause. If it fails, a generation of longevity hype collides with the same 90% preclinical-to-clinical attrition rate that has humbled every revolutionary claim before it. Social media is pricing in immortality. The dosing protocol is pricing in caution measured in 28-day increments between individual patients. One man’s credibility is shattered. His mechanism is funded at $3 billion and counting. The only thing that resolves the contradiction is data from 12 human eyes. End of 2026. Watch the trial, not the narrative.

Alexey Strygin

@strygah

Great pod, but these four facts about longevity need correction: 1) "Longevity Escape Velocity" was coined by mighty @aubreydegrey, not Diamandis. @PeterDiamandis did a great job popularizing it 2) "Multiple clinical trials" for epigenetic reprogramming? There's exactly one: @lifebiosciences Phase 1 that is just kicking off. Everything else is preclinical 3) There is no public data on Altos Labs raising $10B. Most sources claim $3B, with @PitchBook showing $5B. Still massive though 4) "250 human year equivalent" mouse claim has no published support. Epigenetic reprogramming has notoriously bad track record in mice lifespan extensions. Best result: ~7% total lifespan extension by Rejuvenate Bio and original Ocampo's 30% (but in progeria mice) Directionally though @DavidFriedberg is right. Epigenetic reprogramming is very exciting and promising. Just don't oversell it, the subfield has enough hype already. Also (this is very important) David's optimism might give the impression that we are close to solving aging, but it is not true. Progress is slow and field is drastically underfunded. @ChrisWillx great work, great guest - I enjoyed this episode a lot!

Bill Teudt

Director, EH&S

Previously at PCI Pharma Services · San Diego, California, United States

Joined Jun 2026

Marjan Kazemi

IT Procurement Manager

Previously at AIT Worldwide Logistics · San Francisco Bay Area

Joined May 2026

Else Villafuerte

Senior Animal Care Technician

Previously at Proclinical Staffing · Livermore, California, United States

Joined Jun 2026